In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared ...
Jan 15, 2025
0
48
Cancer researchers at the University of Leicester have developed a technique that could predict how well some breast cancer patients will respond to chemotherapy and antibody-directed cancer treatments.
Jan 10, 2025
0
52
A significant advance in breast cancer research has uncovered a key mechanism driving cancer invasion and drug resistance. A University of Liverpool study reveals how two critical molecules present in "HER2-positive" breast ...
Dec 6, 2024
0
81
Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC-NCI-AACR Symposium on Molecular ...
Oct 23, 2024
0
31
For some proteins, a single mutation, or change in its DNA instructions, is all it takes to tip the balance between functioning normally and causing cancer. But despite causing major disease, these slightly mutated proteins ...
Oct 22, 2024
0
65
In a new study published in Circulation: Cardiovascular Quality and Outcomes, researchers at Yale School of Medicine say an artificial intelligence (AI) tool can use electrocardiographic (ECG) images to define the risk of ...
Sep 9, 2024
0
24
A new editorial paper titled "HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity" has been published in Oncotarget.
Jul 16, 2024
0
38
A model co-designed by a professor at Anglia Ruskin University is expected to reduce the need for chemotherapy in up to 38% of breast cancer patients who would previously have been advised to consider the treatment.
Jul 12, 2024
0
47
Combining two cancer drugs may be a promising treatment for advanced metastatic breast cancer, according to the results of a clinical trial published in JAMA Oncology.
Jun 17, 2024
0
58
Monoclonal antibodies are crucial therapeutics due to their high specificity and binding affinity for epitopes (the precise sites where an antibody attaches itself to an antigen, triggering an immune response). Since the ...
Jun 10, 2024
0
26
